About Tempo Therapeutics
Tempo Therapeutics is a private company based in San Diego, California. It has reported $34,171,710 raised in three offerings on Form D since June 2020. Its chief executive is Eric Richman.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Sep 11, 2026 | $14,000,000of $14.5M target | 43 | $325K | DebtRule 506(b) | Form D ↗ |
| Mar 1, 2024 | Mar 15, 2024 | $16,327,664of $16.7M target | 26 | $627K | EquityRule 506(b) | Form D ↗ |
| Jul 10, 2015 | Jun 2, 2020amended Aug 9, 2021 | $3,844,046of $3.8M target | 39 | $98,565 | DebtRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $34,171,710 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Tempo Therapeutics's Form D filed Sep 11, 2026.
Earlier filings also listed Steven Richieri (director, last listed Mar 2024), Robin Sitver (director, last listed Mar 2024), Richard Hancock (director, last listed Mar 2024) and Dino Di Carlo (director, last listed Aug 2021).